Home
 /
Papers
 /
Genomics
 /
Genome-wide Chromosome-specific Aneuploidy Engineering and Phenotypic Characterization with CRISPR-Taiji
Preprint
Open access
Top 1% · Validated by QED

Genome-wide Chromosome-specific Aneuploidy Engineering and Phenotypic Characterization with CRISPR-Taiji

Hugang Feng, Daqi Deng, Rashmi Dahiya +37 more
October 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.04.25.650684
99
%
QED Score
QED Impressions

CRISPR-Taiji makes aneuploidy programmable: using dCas9 alone to engineer chromosome-specific mis-segregation, it delivers the first transcriptomic atlas of human aneuploidies and causally links Chr3p loss to interferon signaling driving ccRCC tumorigenesis.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

CRISPR-Taiji enables efficient chromosome-specific aneuploidy engineering across all 24 human chromosomes through dCas9-induced centromeric chromatin relaxation, generating the first comprehensive transcriptomic landscape of autosomal aneuploidies that reveals both universal stress responses and aneuploidy-specific alterations, including the discovery that chromosome 3p loss specifically drives interferon signaling activation as an early tumorigenic program in clear cell renal cell carcinoma initiation.

See full analysis
Main Claim 1 –

Centromeric dCas9 Targeting Induces Chromosome-Specific Aneuploidy Across 24 Chromosomes

Supporting evidence

  • Centromeric Chromatin Relaxation Drives CRISPRt-Induced Chromosome Mis-Segregation
Main Claim 2 –

CRISPRt Engineers Whole-Chromosome and Arm-Level Autosomal Aneuploidies

Main Claim 3 –

Whole-Chromosome Aneuploidy Triggers Universal Stress and Conserved Specific Programs

Supporting evidence

  • Chromosome-Arm Aneuploidies Partly Recapitulate Whole-Chromosome Transcriptomic Effects
Main Claim 4 –

Chr3p Loss Activates Interferon Responses During ccRCC Initiation

Abstract

Aneuploidy, the gain or loss of chromosomes, is prevalent in both normal and disease conditions, however, experimental approaches to engineer and study aneuploidy remain limited, leaving its functional significance under-characterized. Here, we present CRISPR-Taiji (CRISPRt), an efficient method for inducing chromosome-specific mis-segregation and aneuploidy generation across all 24 human chromosomes via dead Cas9 (dCas9)-induced centromeric chromatin relaxation. Using CRISPRt with scRNA-seq, we generated the first comprehensive transcriptomic alteration landscape of nearly all autosomal aneuploidies at chromosome-arm resolution. This genotype-phenotype map provides causal evidence linking recurrent aneuploidies in clear cell renal cell carcinoma (ccRCC) to molecular and clinical phenotypes observed in patient tumors. Notably, chromosome 3(p) loss, the ccRCC initiating event, specifically drives strong interferon signaling activation, offering novel insights into ccRCC tumorigenesis and immune modulation. Overall, we establish CRISPRt as a simple, efficient and scalable approach for chromosome-specific aneuploidy engineering and characterization in preclinical models to advance aneuploidy research across diverse biological contexts.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?